-
公开(公告)号：US20190092812A1
公开(公告)日：2019-03-28
申请号：US16025382
申请日：2018-07-02
申请人： H. Lee Moffitt Cancer Center And Research Institute, Inc. , University of South Florida , The Scripps Research Institute , Modulation Therapeutics
发明人： Lori Hazlehurst , Christoph Rader , Xiuling Li , Mark McLaughlin
IPC分类号： C07K7/06 , C07K14/705 , C07K1/00
摘要： The present invention concerns cyclic compounds, compositions comprising the cyclic compounds, linkers, a method of preparing a carrying agent:cyclic compound adduct, a method for treating disorders such as proliferation disorders (e.g., malignancies), bone deficiency diseases, and autoimmune diseases, and a method for suppressing the growth of, or inducing apoptosis in, cells (e.g., malignant cells).
-
公开(公告)号：US20160229892A1
公开(公告)日：2016-08-11
申请号：US15024928
申请日：2014-09-26
申请人： H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. , UNIVERSITY OF SOUTH FLORIDA , THE SCRIPPS RESEARCH INSTITUTE OFFICE OF PATENT COUNSEL, TPC8 , MODULATION THERAPEUTICS
发明人： LORI HAZLEHURST , CHRISTOPH RADER , XIULING LI , MARK MCLAUGHLIN
CPC分类号： C07K7/06 , A61K38/00 , C07K1/00 , C07K7/08 , C07K14/705 , C07K14/70596 , C07K2319/21 , C07K2319/30
摘要： The present invention concerns cyclic compounds, compositions comprising the cyclic compounds, linkers, a method of preparing a carrying agent:cyclic compound adduct, a method for treating disorders such as proliferation disorders (e.g., malignancies), bone deficiency diseases, and autoimmune diseases, and a method for suppressing the growth of, or inducing apoptosis in, cells (e.g., malignant cells).
摘要翻译： 本发明涉及环状化合物，包含环状化合物的组合物，接头，制备载体的方法：环状化合物加合物，用于治疗诸如增生性疾病（例如恶性肿瘤），骨缺乏疾病和自身免疫疾病等疾病的方法， 以及抑制细胞（例如恶性细胞）生长或诱导细胞凋亡的方法。
-
公开(公告)号：US11406723B2
公开(公告)日：2022-08-09
申请号：US16575247
申请日：2019-09-18
申请人： H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. , UNIVERSITY OF SOUTH FLORIDA , WAKE FOREST UNIVERSITY , Modulation Therapeutics, Inc.
发明人： David Morse , Robert Gillies , Mark Mclaughlin , Thaddeus Wadas , Hyun Joo Kil , Narges Tafreshi
IPC分类号： A61K51/08 , A61P35/04 , A61K38/00 , C07K7/06 , G01N33/574 , C07K14/705 , A61K38/08
摘要： The subject matter disclosed herein relates generally to cancer therapy and to anti-cancer compounds and imaging agents. More specifically, the subject matter disclosed herein relates to agents that target MC1R and their use in the treatment of cancer. Methods of screening for MC1R targeted agents are also disclosed.
-
公开(公告)号：US20210347826A1
公开(公告)日：2021-11-11
申请号：US16972558
申请日：2019-06-05
发明人： Mark MCLAUGHLIN , Lori HAZLEHURST
IPC分类号： C07K7/64
摘要： Embodiments of the present disclosure generally relate to cyclic peptidomimetic compounds and methods for making the same. Other embodiments relate to a method of treating a disease by administering a pharmaceutically effective amount of a cyclic peptidomimetic disclosed herein, for example to treat cancer.
-
公开(公告)号：US11078235B2
公开(公告)日：2021-08-03
申请号：US16025382
申请日：2018-07-02
申请人： H. Lee Moffitt Cancer Center And Research Institute, Inc. , University of South Florida , The Scripps Research Institute , Modulation Therapeutics
发明人： Lori Hazlehurst , Christoph Rader , Xiuling Li , Mark McLaughlin
IPC分类号： C07K7/06 , C07K7/08 , C07K14/705 , C07K1/00 , A61K38/00
摘要： The present invention concerns cyclic compounds, compositions comprising the cyclic compounds, linkers, a method of preparing a carrying agent:cyclic compound adduct, a method for treating disorders such as proliferation disorders (e.g., malignancies), bone deficiency diseases, and autoimmune diseases, and a method for suppressing the growth of, or inducing apoptosis in, cells (e.g., malignant cells).
-
公开(公告)号：US12060438B2
公开(公告)日：2024-08-13
申请号：US16972558
申请日：2019-06-05
发明人： Mark McLaughlin , Lori Hazlehurst
摘要： Embodiments of the present disclosure generally relate to cyclic peptidomimetic compounds and methods for making the same. Other embodiments relate to a method of treating a disease by administering a pharmaceutically effective amount of a cyclic peptidomimetic disclosed herein, for example to treat cancer.
-
公开(公告)号：US20230211022A1
公开(公告)日：2023-07-06
申请号：US17810956
申请日：2022-07-06
申请人： H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. , Modulation Therapeutics, Inc. , Wake Forest University Health Sciences
发明人： David MORSE , Robert GILLIES , Mark MCLAUGHLIN , Thaddeus WADAS , Hyun Joo KIL , Narges TAFRESHI
IPC分类号： A61K51/08 , G01N33/574 , C07K14/705 , A61K38/08 , A61P35/04 , C07K7/06 , A61K38/00
CPC分类号： A61K51/088 , G01N33/5743 , C07K14/705 , A61K38/08 , A61P35/04 , C07K7/06 , A61K38/00
摘要： The subject matter disclosed herein relates generally to cancer therapy and to anticancer compounds and imaging agents. More specifically, the subject matter disclosed herein relates to agents that target MC1R and their use in the treatment of cancer. Methods of screening for MC1R targeted agents are also disclosed.
-
公开(公告)号：US10011635B2
公开(公告)日：2018-07-03
申请号：US15024928
申请日：2014-09-26
申请人： H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. , UNIVERSITY OF SOUTH FLORIDA , THE SCRIPPS RESEARCH INSTITUTE , MODULATION THERAPEUTICS
发明人： Lori Hazlehurst , Christoph Rader , Xiuling Li , Mark McLaughlin
IPC分类号： A61K38/00 , C07K2/00 , C07K4/00 , C07K5/00 , C07K7/00 , C07K14/00 , C07K16/00 , C07K17/00 , C07K7/06 , C07K7/08 , C07K14/705 , C07K1/00
CPC分类号： C07K7/06 , A61K38/00 , C07K1/00 , C07K7/08 , C07K14/705 , C07K14/70596 , C07K2319/21 , C07K2319/30
摘要： The present invention concerns cyclic compounds, compositions comprising the cyclic compounds, linkers, a method of preparing a carrying agent:cyclic compound adduct, a method for treating disorders such as proliferation disorders (e.g., malignancies), bone deficiency diseases, and autoimmune diseases, and a method for suppressing the growth of, or inducing apoptosis in, cells (e.g., malignant cells).
-
公开(公告)号：US20150105328A1
公开(公告)日：2015-04-16
申请号：US14574776
申请日：2014-12-18
申请人： UNIVERSITY OF SOUTH FLORIDA , H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. , MODULATION THERAPEUTICS
发明人： MARK MCLAUGHLIN , PRIYESH JAIN
CPC分类号： C07K7/54 , A61K38/00 , A61K38/12 , A61K45/06 , C07K7/06 , C07K7/08 , C07K14/001 , G01N33/5008 , G01N33/5011 , G01N33/582 , G01N33/68 , G01N2500/10 , G01N2510/00 , Y02A50/411
摘要： The invention concerns peptoid-peptide hybrids that may act as protein interaction inhibitors (PPIIs). Another aspect of the invention concerns a method for treating a disorder (e.g., an oncologic disorder) in a human or animal subject, comprising administering an effective amount of a peptoid-peptide hybrid (a peptoid body) of the invention, or a composition comprising a peptoid-peptide hybrid, to the subject in need thereof. Another aspect of the subject invention concerns a method for killing or inhibiting the growth of cells (e.g., cancer cells or malaria-infected cells), comprising contacting a cancer cell in vitro or in vivo with an effective amount of a peptoid-peptide hybrid, or a composition comprising the peptoid-peptide hybrid. Another aspect of the invention concerns a method for producing a peptoid-peptide hybrid.
摘要翻译： 本发明涉及可作为蛋白质相互作用抑制剂（PPII）的拟肽肽杂交体。 本发明的另一方面涉及治疗人或动物受试者中的病症（例如肿瘤病症）的方法，包括施用有效量的本发明的拟肽 - 肽杂交体（拟肽体）或包含 一种拟肽 - 肽杂交体。 本发明的另一方面涉及杀死或抑制细胞生长（例如癌细胞或疟疾感染的细胞）的方法，包括使体外或体内的癌细胞与有效量的拟肽 - 肽杂交体接触， 或包含拟肽 - 肽杂交体的组合物。 本发明的另一方面涉及一种生产拟肽 - 肽杂交体的方法。
-
10.发明申请公开(公告)号：US20140322227A1
公开(公告)日：2014-10-30
申请号：US14263631
申请日：2014-04-28
申请人： H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. , UNIVERSITY OF SOUTH FLORIDA , MODULATION THERAPEUTICS
发明人： LORI HAZLEHURST , MARK MCLAUGHLIN , RAJESH R. NAIR
CPC分类号： A61K38/12 , A61K38/08 , A61K38/13 , A61K38/1825 , A61K38/1841 , A61K38/1875 , A61K38/2006 , A61K38/29 , A61K45/06 , C07K7/06 , C07K7/08 , Y02A50/401 , A61K2300/00
摘要： The present invention concerns the use of HYD1 peptides to reduce activated T-cell numbers and/or to promote bone preservation in vivo. The present invention concerns methods of treating a bone deficiency and/or an autoimmune disorder, comprising administering an effective amount of a HYD1 peptide. Another aspect of the invention concerns a pharmaceutical composition comprising a HYD1 peptide and another agent for treating a bone deficiency and/or another agent for treating an autoimmune disorder.
摘要翻译： 本发明涉及HYD1肽在体内降低活化的T细胞数量和/或促进骨保存的用途。 本发明涉及治疗骨缺损和/或自身免疫性疾病的方法，包括施用有效量的HYD1肽。 本发明的另一方面涉及包含HYD1肽和用于治疗骨缺损的另一种药物和/或用于治疗自身免疫性疾病的另一种药物的药物组合物。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.019 秒)
